
Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as in vitro 3D tissue constructs. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.

Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as in vitro 3D tissue constructs. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.
Founded: 2016
Industry: Biotechnology
Product focus: Microfluidics-based high-throughput in vivo and 3D in vitro drug/toxicity screening
Rebrand / aka: Operates as vivoVerse (formerly Newormics LLC)
Headcount (approx.): 12
Early-stage drug discovery and toxicology/safety testing where higher-throughput, lower-cost in vivo and 3D in vitro assays are needed.
2016
Biotechnology
“MassChallenge listed as an investor or supporter”